Pfizer and Tabuk Pharmaceuticals Signed Agreement to Provide Important Medicines to the Saudi Market

In line with Saudi Governments “Vision 2030” outlining plans to achieve a thriving economy & a vibrant society, recently Pfizer Saudi Limited has signed an exclusive commercial agreement with Tabuk Pharmaceuticals (one of the leading pharmaceutical companies in Saudi Arabia and the region in general.

This synergistic venture leverages the local manufacturing capabilities of Tabuk & global promotional capabilities of Pfizer Saudi Limited.

Under this agreement Pfizer Saudi Limited shall have exclusive rights to promote & distribute high of value branded generics.

This unique agreement helps to improve availability of important medicines to the Saudi Society in therapeutic areas like Central Nervous System, Kidney Dialysis/Transplant & Urology.

Pfizer Innovative Health Cluster Lead of Saudi Arabia, Dr. Alaa Gamal said “that Pfizer Saudi Limited is committed to bringing the best in medicines to the Saudi patients and improving access and outcomes for treatment in a cost effective way in above therapeutic areas.”

Dr. Hamad Al Khamees, General Manager Saudi Arabia Tabuk Pharmaceuticals said that “We are excited about this opportunity enabled by the quality of our technical operations. This contributes to further strengthening Saudi Arabia’s local manufacturing industry, and we look forward to more cooperation in the future with Pfizer.”